Focal Segmental Glomerulosclerosis Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Disease Type (Primary FSGS, Secondary FSGS); Treatment (Dialysis, Drug Therapy, Kidney Transplant), and Geography

Report Code: TIPRE00021106 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET INTRODUCTION

Focal segmental glomerulosclerosis (FSGS) is a disease that create scars on kidney tissue develops on the part kidneys that filter waste from the blood (glomeruli). FSGS is caused due to several conditions such as genetic mutations, infection, drug toxicity, and disease condition such as diabetes or sickle cell disease. The FSGS is serious condition that may lead to kidney failure. Therefore, the only treatment options available are dialysis, medication, and kidney transplant.

MARKET DYNAMICS

The focal segmental glomerulosclerosis treatment market growth is estimated to grow due to the growing production of pharmaceutical products, rising research and developments for biopharmaceuticals to enhance the treatment efficacy, and growing generic production. The development of treatment for rarer diseases are likely to serve vital growth opportunities for the market's growth during the forecast period.

MARKET SCOPE

The "Focal Segmental Glomerulosclerosis Treatment Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of focal segmental glomerulosclerosis treatment market with detailed market segmentation by disease type, treatment. The focal segmental glomerulosclerosis treatment market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in focal segmental glomerulosclerosis treatment market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The focal segmental glomerulosclerosis treatment market is segmented on the basis of disease type, and treatment. Based on disease type, the market is classified as primary FSGS, and secondary FSGS. And on the basis of treatment, the market is segmented as dialysis, drug therapy, and kidney transplant.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the focal segmental glomerulosclerosis treatment market based on various segments. It also provides market size and forecast estimates from year 2021 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America (SCAM). The focal segmental glomerulosclerosis treatment market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting focal segmental glomerulosclerosis treatment market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the focal segmental glomerulosclerosis treatment market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the focal segmental glomerulosclerosis treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from focal segmental glomerulosclerosis treatment market are anticipated to have lucrative growth opportunities in the future with the rising demand for focal segmental glomerulosclerosis treatment market in the global market. Below mentioned is the list of few companies engaged in the focal segmental glomerulosclerosis treatment market.

The report also includes the profiles of key players in focal segmental glomerulosclerosis treatment market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •   Variant Pharmaceuticals, Inc.
  •   Pfizer Inc.
  •   ChemoCentryx, Inc.
  •   Retrophin, Inc.
  •   Dimerix Limited
  •   Complexa Inc.
  •   Travere Therapeutics, Inc.
  •   B. Braun Melsungen AG
  •   GlaxoSmithKline plc.
  •   Novartis AG

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Focal Segmental Glomerulosclerosis Treatment Market - By Disease Type
1.3.2 Focal Segmental Glomerulosclerosis Treatment Market - By Treatment
1.3.3 Focal Segmental Glomerulosclerosis Treatment Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. FOCAL SEGMENTAL GLOMERULOSCLEROSIS TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. FOCAL SEGMENTAL GLOMERULOSCLEROSIS TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. FOCAL SEGMENTAL GLOMERULOSCLEROSIS TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. FOCAL SEGMENTAL GLOMERULOSCLEROSIS TREATMENT - GLOBAL MARKET OVERVIEW
6.2. FOCAL SEGMENTAL GLOMERULOSCLEROSIS TREATMENT - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. FOCAL SEGMENTAL GLOMERULOSCLEROSIS TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - DISEASE TYPE
7.1. OVERVIEW
7.2. DISEASE TYPE MARKET FORECASTS AND ANALYSIS
7.3. PRIMARY FSGS
7.3.1. Overview
7.3.2. Primary FSGS Market Forecast and Analysis
7.4. SECONDARY FSGS
7.4.1. Overview
7.4.2. Secondary FSGS Market Forecast and Analysis
8. FOCAL SEGMENTAL GLOMERULOSCLEROSIS TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - TREATMENT
8.1. OVERVIEW
8.2. TREATMENT MARKET FORECASTS AND ANALYSIS
8.3. DIALYSIS
8.3.1. Overview
8.3.2. Dialysis Market Forecast and Analysis
8.4. DRUG THERAPY
8.4.1. Overview
8.4.2. Drug Therapy Market Forecast and Analysis
8.5. KIDNEY TRANSPLANT
8.5.1. Overview
8.5.2. Kidney Transplant Market Forecast and Analysis
9. FOCAL SEGMENTAL GLOMERULOSCLEROSIS TREATMENT MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Focal Segmental Glomerulosclerosis Treatment Market Overview
9.1.2 North America Focal Segmental Glomerulosclerosis Treatment Market Forecasts and Analysis
9.1.3 North America Focal Segmental Glomerulosclerosis Treatment Market Forecasts and Analysis - By Disease Type
9.1.4 North America Focal Segmental Glomerulosclerosis Treatment Market Forecasts and Analysis - By Treatment
9.1.5 North America Focal Segmental Glomerulosclerosis Treatment Market Forecasts and Analysis - By Countries
9.1.5.1 United States Focal Segmental Glomerulosclerosis Treatment Market
9.1.5.1.1 United States Focal Segmental Glomerulosclerosis Treatment Market by Disease Type
9.1.5.1.2 United States Focal Segmental Glomerulosclerosis Treatment Market by Treatment
9.1.5.2 Canada Focal Segmental Glomerulosclerosis Treatment Market
9.1.5.2.1 Canada Focal Segmental Glomerulosclerosis Treatment Market by Disease Type
9.1.5.2.2 Canada Focal Segmental Glomerulosclerosis Treatment Market by Treatment
9.1.5.3 Mexico Focal Segmental Glomerulosclerosis Treatment Market
9.1.5.3.1 Mexico Focal Segmental Glomerulosclerosis Treatment Market by Disease Type
9.1.5.3.2 Mexico Focal Segmental Glomerulosclerosis Treatment Market by Treatment
9.2. EUROPE
9.2.1 Europe Focal Segmental Glomerulosclerosis Treatment Market Overview
9.2.2 Europe Focal Segmental Glomerulosclerosis Treatment Market Forecasts and Analysis
9.2.3 Europe Focal Segmental Glomerulosclerosis Treatment Market Forecasts and Analysis - By Disease Type
9.2.4 Europe Focal Segmental Glomerulosclerosis Treatment Market Forecasts and Analysis - By Treatment
9.2.5 Europe Focal Segmental Glomerulosclerosis Treatment Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Focal Segmental Glomerulosclerosis Treatment Market
9.2.5.1.1 Germany Focal Segmental Glomerulosclerosis Treatment Market by Disease Type
9.2.5.1.2 Germany Focal Segmental Glomerulosclerosis Treatment Market by Treatment
9.2.5.2 France Focal Segmental Glomerulosclerosis Treatment Market
9.2.5.2.1 France Focal Segmental Glomerulosclerosis Treatment Market by Disease Type
9.2.5.2.2 France Focal Segmental Glomerulosclerosis Treatment Market by Treatment
9.2.5.3 Italy Focal Segmental Glomerulosclerosis Treatment Market
9.2.5.3.1 Italy Focal Segmental Glomerulosclerosis Treatment Market by Disease Type
9.2.5.3.2 Italy Focal Segmental Glomerulosclerosis Treatment Market by Treatment
9.2.5.4 Spain Focal Segmental Glomerulosclerosis Treatment Market
9.2.5.4.1 Spain Focal Segmental Glomerulosclerosis Treatment Market by Disease Type
9.2.5.4.2 Spain Focal Segmental Glomerulosclerosis Treatment Market by Treatment
9.2.5.5 United Kingdom Focal Segmental Glomerulosclerosis Treatment Market
9.2.5.5.1 United Kingdom Focal Segmental Glomerulosclerosis Treatment Market by Disease Type
9.2.5.5.2 United Kingdom Focal Segmental Glomerulosclerosis Treatment Market by Treatment
9.2.5.6 Rest of Europe Focal Segmental Glomerulosclerosis Treatment Market
9.2.5.6.1 Rest of Europe Focal Segmental Glomerulosclerosis Treatment Market by Disease Type
9.2.5.6.2 Rest of Europe Focal Segmental Glomerulosclerosis Treatment Market by Treatment
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Focal Segmental Glomerulosclerosis Treatment Market Overview
9.3.2 Asia-Pacific Focal Segmental Glomerulosclerosis Treatment Market Forecasts and Analysis
9.3.3 Asia-Pacific Focal Segmental Glomerulosclerosis Treatment Market Forecasts and Analysis - By Disease Type
9.3.4 Asia-Pacific Focal Segmental Glomerulosclerosis Treatment Market Forecasts and Analysis - By Treatment
9.3.5 Asia-Pacific Focal Segmental Glomerulosclerosis Treatment Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Focal Segmental Glomerulosclerosis Treatment Market
9.3.5.1.1 Australia Focal Segmental Glomerulosclerosis Treatment Market by Disease Type
9.3.5.1.2 Australia Focal Segmental Glomerulosclerosis Treatment Market by Treatment
9.3.5.2 China Focal Segmental Glomerulosclerosis Treatment Market
9.3.5.2.1 China Focal Segmental Glomerulosclerosis Treatment Market by Disease Type
9.3.5.2.2 China Focal Segmental Glomerulosclerosis Treatment Market by Treatment
9.3.5.3 India Focal Segmental Glomerulosclerosis Treatment Market
9.3.5.3.1 India Focal Segmental Glomerulosclerosis Treatment Market by Disease Type
9.3.5.3.2 India Focal Segmental Glomerulosclerosis Treatment Market by Treatment
9.3.5.4 Japan Focal Segmental Glomerulosclerosis Treatment Market
9.3.5.4.1 Japan Focal Segmental Glomerulosclerosis Treatment Market by Disease Type
9.3.5.4.2 Japan Focal Segmental Glomerulosclerosis Treatment Market by Treatment
9.3.5.5 South Korea Focal Segmental Glomerulosclerosis Treatment Market
9.3.5.5.1 South Korea Focal Segmental Glomerulosclerosis Treatment Market by Disease Type
9.3.5.5.2 South Korea Focal Segmental Glomerulosclerosis Treatment Market by Treatment
9.3.5.6 Rest of Asia-Pacific Focal Segmental Glomerulosclerosis Treatment Market
9.3.5.6.1 Rest of Asia-Pacific Focal Segmental Glomerulosclerosis Treatment Market by Disease Type
9.3.5.6.2 Rest of Asia-Pacific Focal Segmental Glomerulosclerosis Treatment Market by Treatment
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Focal Segmental Glomerulosclerosis Treatment Market Overview
9.4.2 Middle East and Africa Focal Segmental Glomerulosclerosis Treatment Market Forecasts and Analysis
9.4.3 Middle East and Africa Focal Segmental Glomerulosclerosis Treatment Market Forecasts and Analysis - By Disease Type
9.4.4 Middle East and Africa Focal Segmental Glomerulosclerosis Treatment Market Forecasts and Analysis - By Treatment
9.4.5 Middle East and Africa Focal Segmental Glomerulosclerosis Treatment Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Focal Segmental Glomerulosclerosis Treatment Market
9.4.5.1.1 South Africa Focal Segmental Glomerulosclerosis Treatment Market by Disease Type
9.4.5.1.2 South Africa Focal Segmental Glomerulosclerosis Treatment Market by Treatment
9.4.5.2 Saudi Arabia Focal Segmental Glomerulosclerosis Treatment Market
9.4.5.2.1 Saudi Arabia Focal Segmental Glomerulosclerosis Treatment Market by Disease Type
9.4.5.2.2 Saudi Arabia Focal Segmental Glomerulosclerosis Treatment Market by Treatment
9.4.5.3 U.A.E Focal Segmental Glomerulosclerosis Treatment Market
9.4.5.3.1 U.A.E Focal Segmental Glomerulosclerosis Treatment Market by Disease Type
9.4.5.3.2 U.A.E Focal Segmental Glomerulosclerosis Treatment Market by Treatment
9.4.5.4 Rest of Middle East and Africa Focal Segmental Glomerulosclerosis Treatment Market
9.4.5.4.1 Rest of Middle East and Africa Focal Segmental Glomerulosclerosis Treatment Market by Disease Type
9.4.5.4.2 Rest of Middle East and Africa Focal Segmental Glomerulosclerosis Treatment Market by Treatment
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Focal Segmental Glomerulosclerosis Treatment Market Overview
9.5.2 South and Central America Focal Segmental Glomerulosclerosis Treatment Market Forecasts and Analysis
9.5.3 South and Central America Focal Segmental Glomerulosclerosis Treatment Market Forecasts and Analysis - By Disease Type
9.5.4 South and Central America Focal Segmental Glomerulosclerosis Treatment Market Forecasts and Analysis - By Treatment
9.5.5 South and Central America Focal Segmental Glomerulosclerosis Treatment Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Focal Segmental Glomerulosclerosis Treatment Market
9.5.5.1.1 Brazil Focal Segmental Glomerulosclerosis Treatment Market by Disease Type
9.5.5.1.2 Brazil Focal Segmental Glomerulosclerosis Treatment Market by Treatment
9.5.5.2 Argentina Focal Segmental Glomerulosclerosis Treatment Market
9.5.5.2.1 Argentina Focal Segmental Glomerulosclerosis Treatment Market by Disease Type
9.5.5.2.2 Argentina Focal Segmental Glomerulosclerosis Treatment Market by Treatment
9.5.5.3 Rest of South and Central America Focal Segmental Glomerulosclerosis Treatment Market
9.5.5.3.1 Rest of South and Central America Focal Segmental Glomerulosclerosis Treatment Market by Disease Type
9.5.5.3.2 Rest of South and Central America Focal Segmental Glomerulosclerosis Treatment Market by Treatment
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS TREATMENT MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. FOCAL SEGMENTAL GLOMERULOSCLEROSIS TREATMENT MARKET, KEY COMPANY PROFILES
12.1. VARIANT PHARMACEUTICALS, INC.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. PFIZER INC.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. CHEMOCENTRYX, INC.
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. RETROPHIN, INC.
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. DIMERIX LIMITED
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. COMPLEXA INC.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. TRAVERE THERAPEUTICS, INC.
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. B. BRAUN MELSUNGEN AG
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. GLAXOSMITHKLINE PLC.
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. NOVARTIS AG
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Variant Pharmaceuticals, Inc.
2. Pfizer Inc.
3. ChemoCentryx, Inc.
4. Retrophin, Inc.
5. Dimerix Limited
6. Complexa Inc.
7. Travere Therapeutics, Inc.
8. B. Braun Melsungen AG
9. GlaxoSmithKline plc.
10. Novartis AG
11. Ligand Pharmaceuticals Incorporated
12. Kern Pharma
13. Merck & Co., Inc.
14. Sanofi
15. Teva Pharmaceutical Industries Ltd.
TIPRE00021106
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking